Thus, we provided clinical evidence supporting the administration of combined therapy of mTOR and VEGFR inhibitors to metastatic uterine PEComa patients and highlighted the application of serial plasma ctDNA profiling for dynamic disease monitoring. This evidence concerns the gene KDR and neoplasm with perivascular epithelioid cell differentiation.